These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 22897589)

  • 1. Selective class I phosphoinositide 3-kinase inhibitors: optimization of a series of pyridyltriazines leading to the identification of a clinical candidate, AMG 511.
    Norman MH; Andrews KL; Bo YY; Booker SK; Caenepeel S; Cee VJ; D'Angelo ND; Freeman DJ; Herberich BJ; Hong FT; Jackson CL; Jiang J; Lanman BA; Liu L; McCarter JD; Mullady EL; Nishimura N; Pettus LH; Reed AB; Miguel TS; Smith AL; Stec MM; Tadesse S; Tasker A; Aidasani D; Zhu X; Subramanian R; Tamayo NA; Wang L; Whittington DA; Wu B; Wu T; Wurz RP; Yang K; Zalameda L; Zhang N; Hughes PE
    J Med Chem; 2012 Sep; 55(17):7796-816. PubMed ID: 22897589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and structure-activity relationships of dual PI3K/mTOR inhibitors based on a 4-amino-6-methyl-1,3,5-triazine sulfonamide scaffold.
    Wurz RP; Liu L; Yang K; Nishimura N; Bo Y; Pettus LH; Caenepeel S; Freeman DJ; McCarter JD; Mullady EL; Miguel TS; Wang L; Zhang N; Andrews KL; Whittington DA; Jiang J; Subramanian R; Hughes PE; Norman MH
    Bioorg Med Chem Lett; 2012 Sep; 22(17):5714-20. PubMed ID: 22832322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phospshoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors: discovery and structure-activity relationships of a series of quinoline and quinoxaline derivatives.
    Nishimura N; Siegmund A; Liu L; Yang K; Bryan MC; Andrews KL; Bo Y; Booker SK; Caenepeel S; Freeman D; Liao H; McCarter J; Mullady EL; San Miguel T; Subramanian R; Tamayo N; Wang L; Whittington DA; Zalameda L; Zhang N; Hughes PE; Norman MH
    J Med Chem; 2011 Jul; 54(13):4735-51. PubMed ID: 21612232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor.
    Venkatesan AM; Dehnhardt CM; Delos Santos E; Chen Z; Dos Santos O; Ayral-Kaloustian S; Khafizova G; Brooijmans N; Mallon R; Hollander I; Feldberg L; Lucas J; Yu K; Gibbons J; Abraham RT; Chaudhary I; Mansour TS
    J Med Chem; 2010 Mar; 53(6):2636-45. PubMed ID: 20166697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of ETP-46321, a potent and orally bioavailable PI3K α, δ inhibitor.
    Martínez González S; Hernández AI; Varela C; Rodríguez-Arístegui S; Lorenzo M; Rodríguez A; Rivero V; Martín JI; Saluste CG; Ramos-Lima F; Cendón E; Cebrián D; Aguirre E; Gomez-Casero E; Albarrán M; Alfonso P; García-Serelde B; Oyarzabal J; Rabal O; Mulero F; Gonzalez-Granda T; Link W; Fominaya J; Barbacid M; Bischoff JR; Pizcueta P; Pastor J
    Bioorg Med Chem Lett; 2012 May; 22(10):3460-6. PubMed ID: 22520259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of 2-oxatriazines as highly potent pan-PI3K/mTOR dual inhibitors.
    Dehnhardt CM; Venkatesan AM; Chen Z; Delos-Santos E; Ayral-Kaloustian S; Brooijmans N; Yu K; Hollander I; Feldberg L; Lucas J; Mallon R
    Bioorg Med Chem Lett; 2011 Aug; 21(16):4773-8. PubMed ID: 21763134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of novel phosphatidylinositol 3-kinase inhibitors: Solubilized 4-substituted benzimidazole analogs of 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474).
    Rewcastle GW; Gamage SA; Flanagan JU; Kendall JD; Denny WA; Baguley BC; Buchanan CM; Chao M; Kestell P; Kolekar S; Lee WJ; Lill CL; Malik A; Singh R; Jamieson SM; Shepherd PR
    Eur J Med Chem; 2013 Jun; 64():137-47. PubMed ID: 23644197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-based optimization of pyrazolo-pyrimidine and -pyridine inhibitors of PI3-kinase.
    Staben ST; Heffron TP; Sutherlin DP; Bhat SR; Castanedo GM; Chuckowree IS; Dotson J; Folkes AJ; Friedman LS; Lee L; Lesnick J; Lewis C; Murray JM; Nonomiya J; Olivero AG; Plise E; Pang J; Prior WW; Salphati L; Rouge L; Sampath D; Tsui V; Wan NC; Wang S; Weismann C; Wu P; Zhu BY
    Bioorg Med Chem Lett; 2010 Oct; 20(20):6048-51. PubMed ID: 20822905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-based design of a novel series of potent, selective inhibitors of the class I phosphatidylinositol 3-kinases.
    Smith AL; D'Angelo ND; Bo YY; Booker SK; Cee VJ; Herberich B; Hong FT; Jackson CL; Lanman BA; Liu L; Nishimura N; Pettus LH; Reed AB; Tadesse S; Tamayo NA; Wurz RP; Yang K; Andrews KL; Whittington DA; McCarter JD; Miguel TS; Zalameda L; Jiang J; Subramanian R; Mullady EL; Caenepeel S; Freeman DJ; Wang L; Zhang N; Wu T; Hughes PE; Norman MH
    J Med Chem; 2012 Jun; 55(11):5188-219. PubMed ID: 22548365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of potent and selective inhibitors of the mammalian target of rapamycin (mTOR) kinase.
    Nowak P; Cole DC; Brooijmans N; Bursavich MG; Curran KJ; Ellingboe JW; Gibbons JJ; Hollander I; Hu Y; Kaplan J; Malwitz DJ; Toral-Barza L; Verheijen JC; Zask A; Zhang WG; Yu K
    J Med Chem; 2009 Nov; 52(22):7081-9. PubMed ID: 19848404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological evaluation of novel analogues of the pan class I phosphatidylinositol 3-kinase (PI3K) inhibitor 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474).
    Rewcastle GW; Gamage SA; Flanagan JU; Frederick R; Denny WA; Baguley BC; Kestell P; Singh R; Kendall JD; Marshall ES; Lill CL; Lee WJ; Kolekar S; Buchanan CM; Jamieson SM; Shepherd PR
    J Med Chem; 2011 Oct; 54(20):7105-26. PubMed ID: 21882832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of 7-(3-(piperazin-1-yl)phenyl)pyrrolo[2,1-f][1,2,4]triazin-4-amine derivatives as highly potent and selective PI3Kδ inhibitors.
    Qin LY; Ruan Z; Cherney RJ; Dhar TGM; Neels J; Weigelt CA; Sack JS; Srivastava AS; Cornelius LAM; Tino JA; Stefanski K; Gu X; Xie J; Susulic V; Yang X; Yarde-Chinn M; Skala S; Bosnius R; Goldstein C; Davies P; Ruepp S; Salter-Cid L; Bhide RS; Poss MA
    Bioorg Med Chem Lett; 2017 Feb; 27(4):855-861. PubMed ID: 28108251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and in vivo evaluation of dual PI3Kβ/δ inhibitors.
    Gonzalez-Lopez de Turiso F; Shin Y; Brown M; Cardozo M; Chen Y; Fong D; Hao X; He X; Henne K; Hu YL; Johnson MG; Kohn T; Lohman J; McBride HJ; McGee LR; Medina JC; Metz D; Miner K; Mohn D; Pattaropong V; Seganish J; Simard JL; Wannberg S; Whittington DA; Yu G; Cushing TD
    J Med Chem; 2012 Sep; 55(17):7667-85. PubMed ID: 22876881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancer.
    Sutherlin DP; Sampath D; Berry M; Castanedo G; Chang Z; Chuckowree I; Dotson J; Folkes A; Friedman L; Goldsmith R; Heffron T; Lee L; Lesnick J; Lewis C; Mathieu S; Nonomiya J; Olivero A; Pang J; Prior WW; Salphati L; Sideris S; Tian Q; Tsui V; Wan NC; Wang S; Wiesmann C; Wong S; Zhu BY
    J Med Chem; 2010 Feb; 53(3):1086-97. PubMed ID: 20050669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphoinositide-3-kinase inhibitors: evaluation of substituted alcohols as replacements for the piperazine sulfonamide portion of AMG 511.
    Lanman BA; Reed AB; Cee VJ; Hong FT; Pettus LH; Wurz RP; Andrews KL; Jiang J; McCarter JD; Mullady EL; San Miguel T; Subramanian R; Wang L; Whittington DA; Wu T; Zalameda L; Zhang N; Tasker AS; Hughes PE; Norman MH
    Bioorg Med Chem Lett; 2014 Dec; 24(24):5630-5634. PubMed ID: 25466188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-based optimization of morpholino-triazines as PI3K and mTOR inhibitors.
    Poulsen A; Williams M; Nagaraj HM; William AD; Wang H; Soh CK; Xiong ZC; Dymock B
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1009-13. PubMed ID: 22197143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. (
    Rageot D; Bohnacker T; Keles E; McPhail JA; Hoffmann RM; Melone A; Borsari C; Sriramaratnam R; Sele AM; Beaufils F; Hebeisen P; Fabbro D; Hillmann P; Burke JE; Wymann MP
    J Med Chem; 2019 Jul; 62(13):6241-6261. PubMed ID: 31244112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid identification of ETP-46992, orally bioavailable PI3K inhibitor, selective versus mTOR.
    Martínez González S; Hernández AI; Varela C; Lorenzo M; Ramos-Lima F; Cendón E; Cebrián D; Aguirre E; Gomez-Casero E; Albarrán MI; Alfonso P; García-Serelde B; Mateos G; Oyarzabal J; Rabal O; Mulero F; Gonzalez-Granda T; Link W; Fominaya J; Barbacid M; Bischoff JR; Pizcueta P; Blanco-Aparicio C; Pastor J
    Bioorg Med Chem Lett; 2012 Aug; 22(16):5208-14. PubMed ID: 22819764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel series of pyrrolotriazine analogs as highly potent pan-Aurora kinase inhibitors.
    Abraham S; Hadd MJ; Tran L; Vickers T; Sindac J; Milanov ZV; Holladay MW; Bhagwat SS; Hua H; Ford Pulido JM; Cramer MD; Gitnick D; James J; Dao A; Belli B; Armstrong RC; Treiber DK; Liu G
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5296-300. PubMed ID: 21802948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and optimization of a series of benzothiazole phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors.
    D'Angelo ND; Kim TS; Andrews K; Booker SK; Caenepeel S; Chen K; D'Amico D; Freeman D; Jiang J; Liu L; McCarter JD; San Miguel T; Mullady EL; Schrag M; Subramanian R; Tang J; Wahl RC; Wang L; Whittington DA; Wu T; Xi N; Xu Y; Yakowec P; Yang K; Zalameda LP; Zhang N; Hughes P; Norman MH
    J Med Chem; 2011 Mar; 54(6):1789-811. PubMed ID: 21332118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.